SalaryGuide
AboutPricingFor Employers

Marketing jobs

2 marketing jobs

3 days ago

Associate Director, Brand Analytics & Forecasting

Madrigal Pharmaceuticals

Waltham, MA (On-site)Full time$171K/yr – $209K/yr
4 months ago

Director, Patient Experience and Access Marketing

Madrigal Pharmaceuticals

Conshohocken, PA (Hybrid)Full time$215K/yr – $263K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs

Associate Director, Brand Analytics & Forecasting

Madrigal Pharmaceuticals

Waltham, MA (On-site)

$171K/yr - $209K/yrIn-houseFull-timeSenior level8+ years exp.
3 days ago

Director, Patient Experience and Access Marketing

Madrigal Pharmaceuticals

Conshohocken, PA (Hybrid)

$215K/yr - $263K/yrIn-houseFull-timeDirector/executive8+ years exp.
4 months ago
Madrigal Pharmaceuticals

Associate Director, Brand Analytics & Forecasting

Waltham, MA (On-site)

$171K/yr – $209K/yrSenior Level8+ years expFull time

Posted 3 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own forecasting and analytics for brand performance across short and long horizons, driving scenario planning, variance analysis, and performance reviews with cross-functional partners.

  • Own forecasting models across in-line and long-range horizons.
  • Lead variance analyses and collaborate with Commercial and Finance teams.

Job Description

Responsibilities

  • Own patient-based and demand forecasting models for assigned brand(s), spanning in-line and long-range horizons.
  • Apply and maintain robust forecasting methodology, including scenario planning, sensitivity analysis, and risk-adjusted forecasting.
  • Partner with Commercial and Finance leadership on performance tracking, KPI dashboards, and business review analytics.
  • Leverage patient-level analytics — line of therapy, patient journey, new vs. continuing patients, switching, persistence, and adherence — to uncover growth drivers, risks, and opportunities.
  • Partner with cross-functional analytics & data team to understand latest on-ground intel and leverage the most relevant data sources to inform assumptions and forecast scenarios
  • Lead variance and root-cause analyses linking actual performance to forecast assumptions and executional drivers, and reconcile patient, sales, and audit perspectives into a single source of brand-performance truth.
  • Manage forecasting vendors or consultants as needed, and mentor junior analysts supporting brand analytics.

Requirements

  • Bachelor's degree in a quantitative, business, or related field; advanced degree (MBA, MS) preferred.
  • 8+ years of experience in pharmaceutical or biotech commercial analytics, including direct experience in brand analytics and/or forecasting.
  • Experience with pharmaceutical demand and patient-based forecasting methodologies.
  • Experience working with syndicated and patient-level data (e.g., IQVIA NPA/NSP, LAAD, DDD, Xponent), claims, and specialty pharmacy data.
  • Hands-on proficiency in SQL and at least one statistical platform (SAS, R, or Python), plus data visualization tools such as Power BI or Tableau.

Preferred

  • Experience supporting specialty or rare disease brands, ideally through a launch.
  • Experience with hands on development of forecast and relevant analytics to track performance
  • Experience with leadership presentation development
  • Experience mentoring or managing junior analyst.

Benefits

  • Full-time employees receive equity, which reinforces our ownership culture and offers meaningful opportunity for our employees to share in the success they help create. By aligning individual and company performance, we empower employees to think like owners, giving them a stake in the organization. Full-time employees are also eligible for comprehensive benefits, including flexible paid time off, medical, dental, vision and life/disability insurance, and 401(k) offerings (i.e., traditional, Roth, and employer match) in accordance with applicable plans. We also offer additional voluntary benefits like supplemental life insurance, legal services, and other offerings. In addition, we offer mental health benefits through our Employee Assistance Program for employees and their family. The company also provides other benefits in accordance with applicable federal, state, and local laws.

Madrigal Pharmaceuticals

3.9 Glassdoor

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Learn more about us at www.madrigalpharma.com

Founded in 2016
Conshohocken, Pennsylvania, USA
871 employees (48 in marketing)
www.madrigalpharma.com
100% recommend to a friend

Traffic Signals

Monthly Visitors
32.4K
Traffic Source Mix
Search
50.2%
Direct
38.5%
Referral
6.1%
Social
3.7%
Paid
1.3%

Headcount Trend

Current headcount: ~871

Marketing Team

Marketing Team Size
43 (5% of company)
Median Career Experience
15.5 years
Median Tenure
2.3 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Kristin Bucklen
Kristin Bucklen
Vice President, Consumer Marketing
At the company for 3 years 6 months
Jennifer Wyher
Jennifer Wyher
Associate Director, Digital Marketing IT Business Partner
At the company for 1 year 4 months
Sean Grim
Sean Grim
Associate Director, HCP Marketing (KOL Engagement)
At the company for 1 year 5 months
Brent C. Schneider
Brent C. Schneider
Executive Director, US Marketing (NASH)
At the company for 4 years 9 months

Funding

Total Funding
$1.6B
Last Raise
Post IPO Debt, 5 months ago

Recent News

Why Madrigal Pharmaceuticals Stock Is Soaring Today
Feb 26, 2025 • The Motley Fool
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Revenue $103.3M, vs. FactSet Est of $99.1M
Feb 26, 2025 • MarketScreener
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Feb 21, 2025 • BioSpace
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Feb 13, 2025 • BioSpace
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Feb 2, 2025 • The Motley Fool
Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial
Jan 27, 2025 • BioSpace
Liver Cirrhosis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
Jan 27, 2025 • EIN Presswire
Madrigal CEO touts 'amazing' sales success of new MASH drug, but stock slumps
Jan 16, 2025 • Philadelphia Business Journal
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
Jan 13, 2025 • BioSpace
Madrigal reports prelim sales for MASH drug
Jan 13, 2025 • Seeking Alpha
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
Nov 10, 2024 • The Motley Fool
Biotech Alert: Searches spiking for these stocks today
Nov 4, 2024 • thefly.com
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Nov 3, 2024 • TradingView
UBS Maintains Buy on Madrigal Pharmaceuticals...
Nov 1, 2024 • Benzinga
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
Oct 30, 2024 • Morningstar, Inc.
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
Oct 30, 2024 • GlobeNewswire News Room
Madrigal Pharmaceuticals management to meet with JMP Securities
Oct 8, 2024 • thefly.com
Short Report: Bearish positioning in Madrigal Pharmaceuticals at 3-month high
Sep 7, 2024 • thefly.com
Is Madrigal Pharmaceuticals Stock a Buy?
Aug 17, 2024 • The Motley Fool
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
Aug 5, 2024 • The Motley Fool